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8ABSTRACT
Measurement quality in medical laboratories was studied with a set of six quality tools:
I Use of reference methods and single donation sera, II Evaluation of uncertainty of
measurement, III Assessment of performance characteristics, IV Internal quality control,
V  Method validation and VI Internal audits.
Using single donation whole blood and sera, routine patient serum and cervical smear
samples, own observations from measurements and questionnaires, manufacturers'
specifications, and data from literature carried out material sampling.
Common clinical chemistry routine methodology for serum total calcium, glucose and
lithium, gynecological cytopathology for Papanicolaou tests and reference methodology
for total calcium and glucose served as the basis for the methods of measurement used.
The applied in vitro diagnostic medical devices consisted of system-dependent and
system-independent calibrators with automated analyzing systems, patient-of-care testing
meters intended for self-monitoring of glucose, control material for daily and proficiency
testing purposes, and traceable reference materials.
Fit-for-purpose statistical methods and software were applied to classify the obtained
data. The principles of international standards and guides were followed in all parts of the
study. The present work was accomplished under co-operation of several European
laboratories and institutes.
The use of the set of tools revealed common important characteristics and points of quality
assurance in medical laboratories across the study. Reference methods and single
donation sera were excellent tools for demonstrating laboratory performance in terms of
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9the state-of-the-art accuracy and trueness in Finnish laboratories. The importance of
personnel skills, method validation and feedback meetings from internal quality control
was emphasized. Need for training to perform internal audits was shown.
This study showed the necessity of the legislative control over the industry around in vitro
diagnostic medical devices. Measurement quality is closely related to traceability,
measurement hierarchy of metrology and evaluation of measurement uncertainty. The
acceptable levels of uncertainty should be expressed as quality goals, which should be
based on biological variation and medical needs.
Keywords: reference methods, quality, uncertainty, IQC, Pap smear, self-monitoring of
blood glucose, SMBG, in vitro diagnostic medical devices, IVDs, lithium, validation,
ISO/IEC 17025, internal audits
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INTRODUCTION
The operation of laboratory medicine in patient care, monitoring and diagnosis is strongly
linked to measurements and observations applied to laboratory samples. Producing
reliable results within a reasonable turnaround time is the ultimate responsibility of
medical laboratories. The total quality of the laboratory service, from the pre-analytical
phase through the analytical phase to reporting, is to support the clinicians' decision-
making.
The proper management of laboratory processes needs supervised personnel doing the
right things in the right way. Well-defined rules are necessary for this management, as the
numerous processes range from sample taking to reporting. International standards, guides
and legislation support the establishment and implementation of quality systems. The
quality of laboratory results, as being the end products of the process, thus strongly
reflects the internal efficiency and the outcome of quality assurance.
Several hundreds of laboratory investigations exist in the production repertoire of modern
medical laboratories. Indeed, the analysing techniques vary from quantitative high
automation to qualitative manual observations, the latter being not of any less importance.
Awareness and demonstration of the existing quality level of all results is of the utmost
necessity. In the global harmonisation of medical laboratory results, demonstrating the
traceability when possible is of great importance.
Quality is not a recent concept and medical laboratories have long traditions in
demonstrating the reliability of the laboratory results. The primary objective of this study
was to introduce a set of quality assurance tools and to demonstrate the appropriate use of
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them in quality assurance. The set of tools reflects only some, of the crucial quality actions
taken in medical laboratories.
In routine quantitative chemistry, the state-of-the-art accuracy of serum calcium and
glucose analyses was shown in Finnish medical laboratories utilising reference methods
and commutable control material (Tool I). In addition to accuracy, i.e. trueness and
precision, the reliability of these common chemistry analyses was evaluated and
expressed as the uncertainty of measurement utilising data and observations from
laboratory routine measurements and data from manufacturer combined to a software
application intended for this use (Tool II). Assessment of analytical performance
characteristics is proposed in the example from Self-Monitoring-of-Blood-Glucose
(SMBG) representing Point-Of-Care-Testing (POCT) (Tool III) and method validation
from therapeutic drug monitoring (Tool V). When introducing internal quality control
(IQC) to the set of tools, patient-related factors affecting re-screening of cytopathology
samples and agreement in senior pathologists´ reviews was highlighted (Tool IV).
In the context of implemented and accredited quality systems, continuous quality
improvement has to cover all quality processes including internal audits (Tool VI).
Amending and upgrading this quality assurance tool has to derive from the opinions of the
laboratory personnel.
Enfocus Software - Customer Support
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REVIEW OF THE LITERATURE
1.  Metrology in laboratory medicine
1.1 The infrastructure of metrology
 Metrology is defined as `science of measurement´ including all aspects both theoretical
and practical with reference to measurements, whatever their uncertainty, and in whatever
fields of science of technology they occur1.
 In 1875, the Convention of the Metre (Convention du Métra) was signed by 17 nations in
Paris as the necessity for global comparability was arisen2,3. Today, after slight
modifications in 1921, this diplomatic treaty between fifty-one member states outlines an
international measurement infrastructure with bodies/organizations and with links to
national measurement institutes. The Convention gives authority to the Conférence
Générale des Poids et Mesures (CGPM), the Comité International des Poids et Mesures
(CIPM) and Bureau International des Poids et Mesures (BIPM) to act in matters of world
metrology. Together with consultative committees the BIPM as being the international
center for metrology, organizes the daily work. The consultative committee for amount of
substance (CCQM) has existed since 1995. The demand for measurement standards of
ever-increasing accuracy, range and diversity and the need to demonstrate equivalence
between national measurement standards are of particular concern in this work. The
Mutual Recognition Arrangement linked to national measurement institutes aims to
increase the knowledge about the agreement between national measurement standards and
specific measurements. Inter-laboratory comparisons or key comparisons coordinated by
CCQM in the field of chemistry are important acts taken on this matter.
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1.2 The International System of Units (SI)
 In 1960, the System International d` Unites, SI became4. The seven dimensionally
independent base units are the meter, the kilogram, the second, the ampere, the Kelvin, the
mole, and the candela. Today, the kilogram, also known as `Le Grand K´, is the only
remaining base SI unit defined by a man-made artifact. The global comparability of
analytical results is in principal established by SI5. The International Federation of
Clinical Chemistry and Laboratory Medicine (IFCC) has recommended the use of SI in
laboratory medicine due to the general acceptance that standardization of routine
measurements should be done by agreement on common basis of metrology6.
1.3 Traceability
 Traceability is internationally defined1 as `the property of the result of a measurement or
the value of a standard whereby it can be related to stated references, usually national or
international standards, through an unbroken chain of comparisons all having stated
uncertainties´. This concept can be understood as a property of the value of the result of a
measurement5, 7. Attaining traceability means providing measurement comparability, i.e.
the ability to compare measurements on a global basis. It is stated that comparability is not
only a problem of traceability to SI units or standards used. Moreover, the concept of
comparability is connected to reference materials, method validation, and proficiency
testing (PT)8.
 
 Traceability in laboratory medicine is not a new issue. In practice, traceability to SI
means that measurement systems have to be designed in a way that they produce results
closely related to the true value. A meaningful measurement system in five distinct parts
has already been introduced in the 1970s9, 10:
 Part 1. A rational, self-consistent system of units of measurement (e.g. the SI system)
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 Part 2. The material to realize in daily practice the defined units and their derivatives (e.g.
the certified reference materials)
 Part 3. The availability of accurate methods of measurements, analysis, or test, based on
the well-characterized materials of part 2 (e.g. IFCC reference methods)
 Part 4. Field or applied methods of measurement, analysis or test (i.e. the methods applied
on a large scale in everyday work)
 Part 5. A method whereby the long-term integrity of the measurement system is assured
(e.g. inter-laboratory comparisons, proficiency testing).
 
Another approach for establishing traceability of the complete analytical procedure is
described in the EURACHEM/CITAC Guide on Traceability in Chemical
Measurements11. The essential activities in establishing traceability are:
· Specifying the measurand and the acceptable uncertainty
· Choosing a measurement procedure of estimating the value
· Demonstrating, through validation, that the measurement procedure includes all the
"influence quantities" that significantly affect the result, or the value assigned to a
standard
· Identifying the relative importance of each influence quantity
· Choosing and applying appropriate reference standards
· Estimating the uncertainty
Today, the directive for in vitro diagnostic medical devices (IVDs)12 strongly supports
traceability in the European community. The essential elements of a calibration hierarchy
to support full calibration traceability to SI are identified in the draft international
standards for IVD calibration traceability, ISO/CD 1751113 and ISO/CD 1815314.
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1.4 Reference materials and reference methods
ISO defines the term `reference material´15: Material or substance one or more of whose
property values are sufficiently homogenous and well established to be used for the
calibration of an apparatus, the assessment of a measurement method, or for assigning
values to materials. It is characteristic for primary reference materials that they are highly
purified chemicals and that they can be directly weighed or measured to produce a
solution whose concentration is exactly known16.
 
 The term `reference method´ is defined15 as: Thoroughly investigated measurement
procedure, clearly and exactly describing the necessary conditions and procedures, for the
measurement of one or more property values that has been shown to have trueness of
measurement and precision of measurements in accordance with its intended use and that
can therefore be used to assess accuracy of other measurement procedures for the same
properties, particularly in permitting the characterization of a reference material.
 
 The purpose of a measurement is to describe a property of the investigated material17. In a
correct metrology measurement system, (i.e. measurement apparatus, reagents, and the
calibrator), this is done by a defined measurement procedure using a calibrator, with an
assigned and traceable value, anchoring the signal(s) through a measurement function to
end up with a measurement result.
 The causes of poor comparability of medical laboratory results are18:
· unspecific measurement procedures
· incorrect calibration of the measurement procedures
· inadequate definition of the quantities.
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The incorrect calibration can be avoided by utilizing suitable (certified) reference
materials and reference methods.
 
 Aiming at the improvement of the result comparability, the awareness for the need of
certified reference materials increased dramatically in the 1990s within many fields of
analytical chemistry including the medical laboratory sector19. The Institute for Reference
Materials and Measurements (IRMM) offers invaluable metrology support to the clinical
chemistry sector20 as well as to other analytical chemistry fields. Many certified reference
materials for use at the medical laboratories are available21, 22. When reference materials
are concerned, `commutability´ means the ability of the material to show inter-assay
changes comparable to those observed in the measurement of the same analyte in human
serum23. Therefore, a possible lack of commutability makes the certified reference
materials useless24.
 
 The hierarchy of measurement methods25 with SI units at the top level and with increasing
bias is: definitive methods (bias ca. 0.1 to 1%), reference methods (bias ca. 1-3%), and
routine methods (bias ca. 5-10%) (Figure 1). The CCQM defines `a definitive method´26
as: A primary method of measurement is a method having the highest metrological
qualities, whose operation can be completely described and understood, for which a
complete uncertainty statement can be written down in terms of SI units. In a practical
meaning, the measurement structure has been described by Tietz10. Definitive methods are
those of highest quality used for validating reference methods and primary reference
materials, i.e. reference materials of highest quality. The observed value obtained by the
field method is linked to the true value obtained by the definitive method through the
traceability chain27, 28.
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Figure 1. The three-level hierarchy of measurement methods described by Uriano
and Cali25.
 Isotope dilution-mass spectrometry (ID-MS) is still the only adequate technique for the
development of definitive methods. Applications of ID-MS have been widely used in
clinical chemistry since the 1970s29,30,31. Some of the advantages of ID-MS are high
precision (imprecision < 0.2%), unbiased nature of the determination, high sensitivity (up
to 10-12g depending upon element and instrumentation), and high selectivity, i.e. possessing
very few interferences32.  In addition to the primary methods of measurements (i.e. ID-MS,
gravimetry, titrimetry, coulometry, freezing point depression) many reference
measurement procedures and candidate reference methods have been developed for
clinical chemistry quantities33, 34, 35, 36. In 1998, European Committee for standardization
defined the presentation of reference measurement procedures37.
 
 In conventional clinical chemistry serum, plasma and whole blood components have been
traditionally the most frequently investigated materials. Most of the measurements still
take place in laboratory environment despite the constant increase in near-patient testing38
         Routine methods ca. 5-10%
        Reference methods ca. 1-3%
                Definitive methods
                     ca. 0.1 to 1%
                             SI
 Bias
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and fast growth of POCT test systems in self-monitoring of diabetes, where no common
basis for comparing the accuracy and precision of these instruments exist31.
 
1.5 Measurements based on identification
Metrology and traceability inhere most often to quantitative analyses. Truly, the
quantitative analysis performed deals with only one part of the measurement spectra
concerned. According to a recent report, the IVD field routinely performs 400 to 600
different amounts of substances (analytes) with full calibration systems with traceability to
SI currently existing for less than 30 (i.e. ca. 5%) of these analytes39.
Pattern recognition, identification, subjective interpretation and classification are common
practice in e.g. clinical pathology, microbiology and molecular biology, or forensic
science. In forensic science, a set of principle of good practice in qualitative analysis has
been reported40. Identification may be described as classification according to specific
criteria41. It often pertains to subjective interpretation on limits such as satisfactory or
unsatisfactory, above or below, or classification into ranges such as amount of particles or
color intensity. In gynecological cytology, the Bethesda System42 updated in 2001 outlines
the terminology for reporting results of cervical cytology. This is crucial to harmonize and
promote effective communication of cervical cytology results from the laboratory to
clinicians and to avoid misunderstanding where `measurement´ and reporting is
metrologically impossible.
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2. The concept of quality and related issues
2.1 The definition of quality
The concept of quality can be described in numerous ways. According to the international
standard ISO 8402, `quality´ is a totality of characteristics of an entity that bear on its
ability to satisfy stated and implied needs43. The achievement of satisfactory quality
involves all stages of the quality loop as a whole. It is notified in the standard43 that the
needs may include: aspects of performance, usability, dependability (availability,
reliability, maintainability), safety, environment, economics and aesthetics. The British
Standard44 points out the various meanings of the quality concept as it is used in different
settings. Quality can be discussed: in a comparative sense, whenever products or services
are ranked on a relative basis; in a quantitative sense as used in technical evaluations, or
in the fitness-for-purpose sense, whenever products or services are evaluated in terms of
their ability to satisfy a given need45.
2.2 Development of quality thinking
The revolution of quality evolved as a consequence of World War II. The first
applications of statistical quality control were taken into use in order to remove
inadequate products intended for military purposes in the US. It became clear that high
quality was produced as a result of inspection and testing procedures46.
The history of quality thinking in health care can be traced back to the middle of 1800th
century. The first colonial hospital, Pennsylvania Hospital, routinely tabulated the clinical
outcomes of its patients in terms of symptoms, cure, or death47. At Massachusetts General
Hospital, one further step was taken in the early 1900´s, as a surgeon, Ernest Codman
developed the `end result system´. He identified reasons for less than optimal outcomes by
categories such as `errors due to lack of technical knowledge or skill´, `lack of surgical
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judgement´, `lack of care or equipment´, or `lack of diagnostic skills´47. In 1917, the
American College of Surgeons took the initial attempt towards improved health care
quality. This college established a hospital standardization programme45. The Minimum
Standard was published in 1919 because of this work, which included specific
requirements for diagnostic and therapeutic facilities. It states: The diagnostic and
therapeutic facilities under competent supervision available for the study, diagnosis, and
treatment of patients, should include, at least: (a) a clinical laboratory providing chemical,
bacteriological, serological, and pathological services; (b) an X-ray department providing
radiographic and fluoroscopic services.
During the pre-penicillin era in the 1930s, it became obvious to require external quality
assessment (EQA) schemes for syphilis serology to limit the administration of arsenic and
mercury and simultaneously to minimize toxic chemotherapy48.  In 1950, Levey and
Jennings introduced the use of control charts in medical laboratories49 according to the
ones previously used in industrial processes and known as Shewhart plots50. Westgard
rules were developed in the early 1980s to facilitate the IQC run by the medical
laboratory professionals51. Since the “quality-thinking” has grown in the fields of
laboratory medicine as well as in the industry manufacturing diagnostic products52. Due to
the positive attitude to the concept of quality, monitoring and assessing the laboratory
performance has been run for decades by professionals in medical laboratory sector
mainly by focusing on well-established quality tools53, such IQC51 and EQA54,55.
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2.3 Quality management
`Quality management is defined as the part of the overall management functions that
determines and implements quality policy43. It was gradually realized that by doing the
right things from the beginning, i.e. relevantly, timely, and effectively from economic point
of view, would satisfy the needs set and stated by the many stakeholders of medical
laboratories.  This led to understanding of total quality management. Westgard’s and his
colleagues’ work is a remarkable milestone in the development of total quality
management in laboratory medicine56.
Throughout the 1980s and the 1990s, much attention has been paid to principles of quality
management associated with organizational structures, responsibilities, procedures,
processes, and resources57. Two distinct systems of total quality management applicable
to medical laboratories exist: accreditation and certification. By definition, `accreditation´
is a procedure by which an authoritative body gives formal recognition that a body or
person is competent to carry out specific tasks58. On the contrary, `certification´ is a
procedure by which a third party gives written assurance that a product, process or
service conforms to a specific requirement58. In common usage to `accredit´ means to
certify or guarantee someone or something as meeting required standards and to `certify`
means to endorse or guarantee that certain required standards have been met59. The
requirements are written in documents called ‘standards` usually implemented by
international or national organizations. The concept `standard´ is described as a document,
established by consensus and approved by a recognized body, that provides, for common
and repeated use, rules, guidelines or characteristics for activities or their results, aimed
at the achievement of the optimum degree of order in a given context60.
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2.4 Laboratory accreditation and certification
Globally, the organizations accrediting or certifying medical laboratories are of different
types, i.e. governmental or authoritative organizations. The development in laboratory
accreditation started, as it became clear to the United States Congress that unsatisfactory
testing was performed within health care sector61. Consequently, the College of American
Pathologists (CAP) initiated the first accreditation scheme in 1961 specially designed for
medical laboratories: the Laboratory Accreditation Programme (LAP). Today, the CAP
programme62 is recognized by the Joint Commission on Accreditation of Healthcare
Organizations (JCAHO)63 and has a decision authority under the Clinical Laboratory
Improvement Amendments of 1988, CLIA´8864.    
In Australia the National Association of Testing Authorities (NATA) as a principal
inspection agency, has experience with accreditation for over 50 years mainly for the
benefit of Australian industry, government, and the community65. A medical testing
program was established by NATA in 1983 to accredit pathology facilities. The
Australian principles of accreditation follow the ISO 9000 standard series66 and ISO/IEC
Guide 2567. The Canadian Council on Health Services Accreditation (CCHSA) introduced
a Client Centered Accreditation Program in 199568 focusing on the implementation of
Total Quality Management in medical laboratories, but no federal approach has yet been
developed.
 In addition to patient care the scope of medical laboratory analyses are also included in
medical trials. In this context, medical laboratories have to follow good laboratory
practice (GLP) standards as tests are performed in the pre-clinical phase. In European
countries the GLP directive is based on the principles based on the Organisation for
Economic Co-operation and Development, the OECD guideline69, while the laboratories
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involved with medical trials are controlled by the U.S. Food and Drug Administration
(FDA). The National Committee for Clinical Laboratory Standards (NCCLS) in the US
contributes to guidelines for health care professionals and manufacturers in terms of GLP
and medical laboratory testing45.
 
To demonstrate the required quality procedures, European medical laboratories started to
take actions during the 1990s in developing their quality systems according to EN 4500170
based on the ISO/IEC Guide 2567 or ISO 9000 standard series66. The first medical
laboratories were accredited in Sweden in 1992 by SWEDAC, the Swedish accreditation
body71. Since then, the number of accredited laboratories, representing disciplines of
clinical chemistry, clinical microbiology, blood banking, and pathology has been growing
exponentially in the Nordic countries. Today, more than twenty medical laboratories in
Finland have fulfilled the accreditation requirements assessed by FINAS72, the Finnish
Accreditation Service that together with other accreditation bodies is a member of
European co-operation for Accreditation (EA)73. In the United Kingdom, medical
laboratories follow the national standards set by the Clinical Pathology Accreditation
(CPA)74, which serves also as the national accreditation body. Guides and
recommendations were established in many countries by international, national,
organizational, and professional groups to facilitate this demanding work75, 76, 77, 78, 79, 80, 81,
82. In addition to analytical issues, guidance for documenting and implementing some
special actions has been taken in account. These actions include e.g. internal audits76, 84, an
important management tool which medical laboratories might not have been so familiar
with before83.
The new international standard ISO/IEC 17025, General requirements for testing and
calibration laboratories84, replaced the criteria of the EN 45001 and ISO/IEC Guide 25
standards for laboratory accreditation by the end of 2002.
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In co-operation between ISO, the US standardization body, American National Standards
Institute (ANSI), and the NCCLS, the ISO Technical Committee 212, ISO/TC212 has
worked out the first International Standard for Quality management in the medical
laboratories EN/ISO 1518985. The proposed standard has been prepared to specify the
requirements for the quality management of a medical laboratory and to cover all
examinations and provide guidance for laboratory procedures to ensure quality in medical
laboratory examinations86, 87. It has been claimed that this standard will bring the quality
management in medical laboratories closer to total quality management than previous
standards88.
2.5 Requirements set for manufacturers and products
It is declared in the Essential requirements, Annex 1 in the European Community, EC
directive set for IVDs12 that:
The devices must be designated and manufactured in such a way that they are suitable for
the purposes referred to in Article 1(2)(b), as specified by the manufacturer, taking
account of the generally acknowledged state of the art. They must achieve the
performances, in particular, where appropriate, in terms of analytical sensitivity,
diagnostic sensitivity, analytical specificity, diagnostic specificity, accuracy,
repeatability, reproducibility, including control of known relevant interference, and limits
of detection, stated by the manufacturer. The traceability of values assigned to calibrators
and/or control values must be assured through available reference measurement
procedures and/or available reference materials of a higher order.
The objective of IVDs´ design is to produce medically useful results. In this context, well-
defined laboratory quality specifications play an important role. Manufacturers
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conforming to ISO quality system standards must follow a disciplined design control when
developing a new IVD system89, 90, 91.
Design control has five general steps92:
· define user requirements
· translate user requirements into design specifications
· design and develop the product to satisfy the requirements and design specifications
· verify the product meets the specifications
· validate the product by demonstrating that the user requirements are met.
The prime objective of design control in the development of medical devices is to deliver
the product to market economically and have it perform safely and effectively for its
intended use93. There are close relations between industry and the users of IVDs, i.e.
professionals at the laboratory workbench or patients performing self-monitoring94.
The FDA Design control guidance95 for medical device manufacturers has been developed
by the contribution of the Global Harmonization Task Force96 (GHTF) Study Group 3. The
GHTF was formed in 1992 to further this effort. The GHTF includes representatives of the
Canadian Ministry of Health and Welfare; the Japanese Ministry of Health and Welfare;
FDA; industry members from the European Union, Australia, Canada, Japan, and the
United States; and a few delegates from observing countries. The ultimate purpose of
GHTF is to respond to the growing need for international harmonization in the regulation
of medical devices. The CLIA’88 regulations categorize tests on the basis of the
complexity of the test methodology97:
· waived tests
· tests of moderate complexity
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· tests of high complexity.
3. Evaluation and expression of measurement quality
3.1 Method validation
According to the standardized definition43 used for `validation´, this evaluation process is
confirmation by examination and provision of objective evidence that the particular
requirements for a specific intended use are fulfilled.  A process very close to validation,
i.e. `verification´43 is performed when a laboratory wishes to confirm that specified
requirements have been fulfilled. In laboratory medicine, validation can be understood as
an adequate examination of a laboratory or a POCT method of measurement intended for a
clinical investigation, i.e. monitoring or diagnosis. Clinical laboratory professionals meet
the need for selection and evaluation of either new or modified methods recurring.  At the
time, both standardized and non-standardized methods shall be covered98, 99.  Good
laboratory practice postulates well-established processes prior to method adoption to
routine use. According to the modern approach of a new method introduction begins with
establishment of need, method selection, and quality goal setting27. The six Valid
Analytical Method -principles have been introduced in the EURACHEM Guide for The
Fitness for Purpose of Analytical Methods99. The first principle stresses that analytical
measurements should be made to satisfy an agreed requirement regarding measurements
made under well-defined quality control and quality assurance procedures. Thus, an
operational definition is needed first to agree on46, 75.
Due to its demanding nature, the outlines of validation (and verification) shall consist of:
· planning, timing and follow-up
· performance according to reasonable schemes
· documentation
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· reporting
· acceptance.
In the laboratory medicine field, the first method evaluation schemes100 were introduced in
the 1970s. Several experts and expert groups have since then worked out evaluation
protocols for medical laboratories and IVD manufacturers101, 102, 103, 104, 105.
3.2 Analytical performance
From the medical laboratory perspective, information on the reliability of results is
necessary for several reasons. First, a laboratory professional has to evaluate the
fulfillment of quality goals in method validation, establishing of IQC or in running daily
quality control106, 107, 108. Secondly, it is important that the result of a measurement is
accompanied with information of the error or uncertainty (within a defined confidence
interval)109, 110, 111. Thirdly, the competence of the laboratory may be, and is often judged
against the analytical performance in EQA112 or third party assessment according to
available international standards84, 85.  Common understanding and expression of terms is
important in any field of science and technology113. The pivotal ISO definitions
characterizing analytical performance exist as the following concepts114:
· trueness - The closeness of agreement between the average value obtained from a
large series of test results and an accepted reference value
· precision - The closeness of agreement between independent test results obtained
under stipulated conditions
· accuracy - The closeness of agreement between a test result and the accepted
reference value
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· uncertainty - An estimate attached to a test result, which characterizes the range of
values within the true value, is asserted to lie.
All testing from pre-analytic phase to the reporting involves with error and uncertainty
sources. In quantitative analyses, the reliability of the measurement quality is expressed as
random error (i.e. precision) and systematic error (i.e. trueness, or bias)109. The
combination of these two errors is comprehended as total error, TE (i.e. accuracy). For
this reason, it is important to distinguish the difference between error and uncertainty as
stressed in the available guides115, 116, 117, 118. Current international standards84, 85 applied to
medical laboratory accreditation and quality management describe clearly the
requirements for evaluation and calculation of the uncertainty of measurement whenever
possible. In modern laboratory practice, the expression of the uncertainty of measurement
has become an inevitable concept109, 119. In qualitative analyses, the results are reported on
a nominal or ordinal scale. Reports in laboratory medicine often include various
categorical statements. Uncertainties of non-quantitative tests in many areas41, 120, 121 are
expressed as alternative reliability measures such as,
· false positive rate - FPi/(TNii + FP)
· false negative rate - FNiii/(TPiv + FN)
· sensitivity - TP/(TP + FN)
· specificity - TN/(TN + FP)
· efficiency - (TP + TN)/(TP + TN + FP + FN)
· Youden index122 - sensitivity + specificity - 100
· likelihood ratio - (1 - false neg. rate)/(false pos. rate)
· Bayes posterior probability123,
iFP=false positive, iiTN=true negative, iiiFN= false negative, ivTP=true positive.
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3.3 Laboratory performance and quality goals
Medical laboratories have long traditions in demonstrating their analytical quality by
means of EQA or PT124. The term EQA is more established in Europe among medical
laboratory professionals. Since the early 1950s, EQA125 has provided an essential quality
assurance tool complementary to IQC in comparing the performance between laboratories.
Starting with national EQA surveys the history of Labquality in Finland can be traced back
to the early seventies126. ISO has published ISO/IEC Guide 43 on Proficiency Testing by
Inter-laboratory Comparisons including examples of statistical methods for treatment of
PT data127.
Today, EQA schemes cover several disciplines in the medical laboratory sector
worldwide. The goals of EQA are explicit128, 129, 130, 131, 154:
· to maintain the long-term accuracy of the analytical methods
· to evaluate participant performance
· to train participants.
In the European Community, the International Evaluation Programme (IMEP) organized by
IRMM has promoted inter-laboratory comparisons in co-operation with reference/national
metrology institutes and EQA organizers132, 133, 134, 135.
Assessment of laboratory performance is closely linked to the set goals. A working group
under the European Group for the Evaluation of Reagents and Analytical Systems in
Laboratory Medicine (EGE-Lab) has recommended applying the biological approach as
the basis for analytical specifications for routine method bias and precision, and total
error136. The members of the External Quality Assessment Working Group A on analytical
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quality goals in laboratory medicine recommends that the total allowable error, TEa is
calculated from the following equation137:
TEa = 1.65 * CVA  + [BA] (a<0.05),
CVA, and BA are desirable quality specifications for imprecision
146 and bias152.
Optimally, if the laboratory uses either two different methods (or two different
instruments) for the same analyte, the allowable difference between them should not
exceed one third of the intra-individual biological variation of the analyte138.
In external quality assessment schemes (EQAS), biological data can be used to set
specifications for the fixed limits of acceptance139:
EQA-limit = 2.33 * CVA  + [BA] (a<0.01)
However, the limits of acceptance and the criteria for setting the limits vary between
countries140, 141.  Further, it has been proposed that more stringent quality specifications,
TEa < 1/5 * EQA-limit should be used when reference methods are concerned
142.
As monitoring of a patient is concerned, it is most important that the analytical
variation143, CVA should not increase the variability of test results also influenced by the
intra-individual biological variation, CVI
144
 and pre-analytical variation, CVPRE
145.
The first concept for tolerable analytical variation was proposed in 1970146:
CVA  < 0.5 * CVI.
In therapeutic drug monitoring, a model based on pharmacokinetic theory is used147:
CVA  < 0.25[(2
T/ t - 1)/(2T/ t + 1)] * 100,
T is the time interval between doses and t is the average elimination half-life. The
equation above shows that drugs with small dosing interval or long half-life require better
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precision. The goal is that methods should have no bias and only true values should be
generated. Therefore, goals for precision should be more or less equal to goals for total
analytical error, desirably with index of fiduciality, i.e. CVA/0.5 * CVI., less than 1.0
148
 .
Reference change value, RCV must exceed the inherent variation due to biological, and
analytical variation in the assessment of the patient’s status149:
RCV > 20.5 · z · [CVA
2 + CVI
2]0.5,
z is for example, 1.96 for p < 0.05 and 2.56 for p < 0.01.
A clinician usually compares the test results either to clinical consensus guidelines, e.g.
glucose150, or to population-based reference limits151 to be able to reveal illness as early
as possible. The following definition for analytical bias, [BA] based on the group
biological variation has been introduced152:
[BA] < 0.25 [CVI
2 + CVG
2]0.5,
CVG is the inter-individual biological variation (i.e. between-subject variation).
This criterion for bias is interpreted as follows: 120 individuals are selected for a
reference population as recommended by IFCC153. Then the maximum bias allowable to
achieve the maximum acceptable percentage of the population outside each limit for the
0.90 confidence interval of each of the reference limits (mean +1.96 s), which equals to
4.4%.
It has to be emphasized that these currently available quality specifications are applied
only for routine clinical chemistry and that no global specifications are available for
POCT until now154, despite of the on-going standardization work on establishing
performance criteria for in vitro blood glucose monitoring systems155. Working Group 3
(WG 3) of the International Standards Organization Technical Advisory Group 212 (ISO
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TAG 212) administered by NCCLS has developed a draft document on analytical goals156.
According to this document, a well-established quality management plan must take into
account economic and regulatory needs in addition to the most important basis of
desirable analytical performance goals, the medical needs. A hierarchical approach to
classification of strategies is presented in the Consensus Statement157 from the Stockholm
Consensus Conference in 1999. The objective of the Stockholm meeting was to reach
consensus on the setting of global quality specifications in laboratory medicine. This was
achieved successfully, resulting in unanimous agreement between the participants. Where
available, and when appropriate for the intended purpose, models higher in the hierarchy
are to be preferred to those at lower levels. The concept of such a hierarchy is
described158.  This hierarchy has also been proposed by the ISO/TC 212 WG 3 subgroup
on `Analytical Performance Goals Based on Medical Needs´.
Quality goal setting in measurements based on pattern recognition and subjective
interpretation, like cytopathology is more complex. First, the laboratory report is a result
of several affecting factors and evaluated parameters. Contradictory reports appear on
sensitivity and specificity of i.e. conventional Papanicolaou (Pap) testing by
cytotechnologists120, 159. Self-evidently, the most stringent goal for pathology is that no
false diagnosis should ever be done.
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AIMS OF THE STUDY
The objective of this study was to identify and assess an adequate set of quality assurance
tools in demonstrating and improving the reliability of measurements performed at modern
medical laboratories in context with current international standards, guides and
recommendations.
The set of tools and specific examples of their use were in the studies I-VI:
I Tool: Use of reference methods and single donation sera
Example: The use of this tool was demonstrated by assessing the state-of-the-
art trueness and precision of serum total-calcium and glucose routine
measurements in Finnish medical laboratories. The results were compared to
reference method values obtained by ion chromatography and isotope dilution-gas
chromatography-mass spectrometry (ID-GC-MS).
II Tool: Evaluation of the uncertainty of measurement
Example: The uncertainty of measurement was evaluated in the determination
of the substance concentrations of calcium and glucose in serum in common routine
clinical chemistry to emphasize the need for expressing measurement reliability.
III Tool: Assessment of performance characteristics
Example: The analytical performance of two different POCT meters
commonly applied in SMBG was assessed. The performance characteristics were
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compared to the available analytical goals and to the fit-for-purpose
specifications.
IV Tool: Internal quality control, IQC
Example: Factors affecting the outcome of IQC procedures applied in
cytopathology by pattern recognition and subjective interpretation as methods of
measurement were investigated.
V Tool: Method validation and result level verification
Example: A method validation procedure was introduced in the field of
therapeutic drug monitoring. The determination of the substance concentration of
lithium in serum was taken as an example.
VI Tool: Internal audits
Example: Opinions of personnel on the internal audit process were surveyed
at a medical laboratory.
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MATERIALS AND METHODS
1. Material sampling
1.1 Serum samples
Single donation sera were obtained from six voluntary males (I). All donors were
tested to be negative against human immunodeficiency 1 and 2 virus and Hepatitis C
virus antibodies, Hepatitis B surface antigen and syphilis prior to any further actions
taken. The blood donations took place under ethical conditions at the Helsinki
University Central Hospital. After separating from the blood cells, the native serum
was filtrated through a tuft of glass wool. The material obtained was carefully mixed,
then divided into aliquots before freezing in tightly capped plastic tubes. This was to
ensure the homogeneity and the stability of the analytes to be studied: calcium and
glucose. Six aliquots of each sample, frozen on solid carbon dioxide, CO2 were
shipped to the reference laboratories at the University of Gent, Belgium and to the
participating laboratories of QSL-Finland study (I).
Four voluntary healthy adults donated whole blood 3 x 5 ml (III). Two adults were
fasting before phlebotomy and two were on normal diet. Four glucose levels were
prepared: lower hypoglycemic, hypoglycemic, euglycemic and hyperglycemic level.
The hypoglycemic levels derived from incubating the whole blood samples maximally
18 hours at room temperature. The euglycemic level was from one of the non-fasting
donors and the sample was appropriate as such. The hyperglycemic level was obtained
by spiking the blood drawn from the other non-fasting donor with 750 mmol/l of D-
glucose. After level adjustments, all samples were treated in an equal way (III).
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The Medix Laboratories Ltd. (Espoo, Finland) (Medix) patient sample pool served as
the source of testing material for 62 serum lithium samples (IV). The reported serum
lithium concentrations in mmol/l were recorded for method comparison (V).
During 1996-1999 the cytopathology sample pool at Medix was used in the sampling of
119 of 87409 Pap smears retrospectively double-screened by cytotechnologists and
354 of 87409 Pap smears reviewed by pathologists as internal quality control (IV).
From the selected and double-screened Pap smears, the use of intra-uterine device,
patient age (< 47 year and > 47 year), and hormone replacement treatment were filed
(IV).
1.2. Other test material
The raw absorbance data was obtained from two common routine clinical chemistry
spectrophotometric methods used at Medix for determination of the amount of substance
of calcium and glucose in serum: o-cresolphthalein complexone for calcium, and the
enzymatic reference method with hexokinase for glucose (II). The necessary
information about calibrators and instrument specifications were from the manufacturer
of the measurement system (Roche Diagnostics Ltd., Mannheim, Germany) (II).
Laboratory personnel experiences from vertical and horizontal audits during 1996-2000
at Medix served as the basis of studying the fulfillment of common quality management
procedures. The brief questionnaire resulted in 74 replies from 120 employees at
Medix (VI).
Enfocus Software - Customer Support
37
2. Principles of measurements in routine methods
The following principles of measurement for the determination of calcium in the serum
samples were atomic absorption spectrometry, liquid or reflectance absorption
spectrophotometry, flame photometry, and potentiometry, ion selective electrode (I, II).
Medix and other Finnish collaborators applied amperometric, absorption
spectrophotometric and reflectance methods for serum and whole blood glucose
measurements (I, II, III). Morphological investigation was the principle of
measurement technique in the cytopathology study (IV).
Direct ion selective electrode applications were used for serum lithium measurement
(V).
3. Reference methods
A primary reference method, ID-GC-MS was used for serum glucose (I). Ion
chromatography was used to obtain the reference method values for serum calcium (I).
The reference method for the investigation of Pap smears: Papanicolaou´s staining and
cell morphology based on the Bethesda System42was used routinely in the cytology
study (IV). Reference method values for serum lithium PT samples were obtained
operating under the principles of flame emission photometry (V).
4. In Vitro Diagnostic Medical Devices
4.1 Calibration devices
Both system-dependent and system-independent calibrators were used in the QSL-
Finland study (I). The applied glucose and calcium methods were calibrated against
commercially available D-glucose materials and respectively against calcium materials
(I). Calibrator for automated systems (C.f.a.s.) (Roche Diagnostics Ltd.) was used for
Enfocus Software - Customer Support
38
calibration of the measurement of serum glucose hexokinase method (II, III) and
respectively for the calibration of the o-cresolphthalein complexone method to measure
calcium in serum (II).
The ion selective electrode setups: CobasÒ Intergra ISE Module (Roche Diagnostics
Ltd.), Microlyte 6 ISE (Kone Instruments, Espoo Finland) and Chiron 654 Na+/K+/Li+
(Chiron Diagnostics Ltd., Halstead, Essex, U.K.) were equipped with their own system
solutions and calibrators and were purchased from the respective manufacturers (V).
According to the manufacturer, GlucoTouchTM (Life Scan Inc., Milpitas, CA, U.S.A.)
was "factory-calibrated" to the plasma glucose level with 21 calibration events against
YSI 2700 Glucose Analyzer (YSI Incorporated, Yellow Springs, OH, U.S.A) (III).
GA-1140 Glucose AUTO & STAT (KDK Corporation, Kyoto, Japan) was used as the
reference system in the calibration of Super Glucogard IITM test strips (III).
4.2 Measurement devices
Medical laboratory instrumentation intended for routine use was applied in QSL-
Finland study (I). CobasÒ Integra 700 clinical chemistry analyzer (Roche Diagnostics
Ltd.) equipped with ion selective electrode module was used for the measurements of
serum calcium (II), serum lithium (V), and serum glucose (II, III). POCT glucose
meters used for SMBG were GlucoTouchTM and Super GlucoGard IITM (III). The two
other ion selective electrode setups were Microlyte 6 ISE and Chiron 654 Na+/K+/Li+
(V). Common light microscopes represented measurement devices in the cytopathology
study (IV).
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4.3 Control material
PT samples of past schemes were purchased from Labquality Ltd. (Helsinki, Finland)
and from Murex Biotechnology Ltd. (Dartford, Kent, U.K.), currently under the
company name of Bio-Rad Laboratories Inc. (Hercules, CA, U.S.A).  The PT samples
were either liquid or lyophilized material and of human origin. DaytrolTM from
Labquality Ltd. and system-dependent control materials from Roche Diagnostics Ltd.
were used in daily IQC (II, III, V).
System-dependent control solutions were used in POCT: a one-level control with
GlucoTouchTM, respectively a low, normal and high level controls with Super
Glucogard IITM (III).
4.4 Reference materials
A standard reference material, SRM 909b (National Institute of Standards &
Technology, NIST, Gaithersburg, MD 20899, U.S.A.) was used as an internal quality
control sample (I) and a reference material to evaluate the bias (III). SRM 917a D-
glucose from NIST was applied in spiking of whole blood to attain a hyperglycemic
level (III). Lithium chloride, p.a. 99% purity (Merck & Co., Inc., Darmstadt, Germany)
was used in the preparation of a 50 mM solution, then serially diluted and used for
linearity testing in a range between 0.06 mmol/l and 4.01 mmol/l of lithium (V).
5. Software applications, statistical methods and calculations
The GUM WorkbenchÒ software, version 1.3 (Metrodata GmbH, Grenzach-Wyhlen,
Germany) was used to facilitate the calculations of the combined standard uncertainties,
uc and expanded uncertainties U (II).
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The Analyse-ItÒ with Microsoft Excel 5.0 for Windows software (Analyse-It Software
Ltd., 40 Castle Ings Gardens, Leeds, U.K.) was used to:
· test the linearity by ordinary linear regression (V)
· test the normality of the laboratory test result data by Shapiro-Wilk W test (III, V)
· judge the agreement between the studied method setups with Altman-Bland plots
(V)
· compare between methods by Passing-Bablok regression analysis (V).
The Marchandise equation was applied in the evaluation of the biases from the PT
outcome (V).
The significant changes expressed in mmol/l were calculated using the generally
applicable quality specifications based on biological variation and subject-based
reference intervals (III).
SPSSÒ for Windows version 8.0 (SPSS Inc., Chicago, IL, U.S.A) was used to:
· test the intra- and inter-observer variations by the Linear-by-linear Association
(IV)
· assess the effect of intra-uterine device, patient age and hormone replacement
treatment on re-screening parameters (IV)
· evaluate the re-viewing agreement between pathologists by cross-tabulating (IV).
MicrosoftÒ Excel for Windows version 5.0 (Microsoft Corporation, CA, U.S.A.) was
for all basic calculations and tabulating (I-VI).
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6. Co-operating laboratories, institutes and commercial companies
Medical laboratories in 21 Finnish hospitals and clinical institutes participated
voluntarily in the QSL-Finland study (I). Other essential co-operators were:
· Helsinki University Central Hospital, Department of Clinical Chemistry (Helsinki,
Finland) (I)
· Laboratories for Analytical Chemistry and Medical Biochemistry and Clinical
Analysis, Faculty of Pharmaceutical Sciences, University of Gent (Gent, Belgium)
(I)
· Diacor, The Deaconess Institute Clinical Laboratory (Helsinki, Finland) (I, III)
· Medix Laboratories Ltd. (Espoo, Finland) (II, IV, V, VI)
· Kanta-Häme Central Hospital Laboratory (Hämeenlinna, Finland) (III)
· Rinnekoti Foundation Laboratory (Espoo, Finland) (V)
· IRMM, Joint Research Centre, European Commission (Geel, Belgium) (II)
· Roche Diagnostics (Mannheim, Germany and Espoo, Finland) (II).
7. International standards and guides
Outlines of pre-analytic and analytic technical and managerial procedures were tangent
to general requirements set to competent testing laboratories in the ISO Guide 2567 and
the standard EN 4500170 (I, III, IV, V, VI). The principles laid down in the
EURACHEM/CITAC Guide115 were followed in the evaluation of the uncertainty of
measurement (II). Good laboratory practice was followed in all experimental work (I-
VI).
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RESULTS
1. Primary results from the use of the tools I-VI
1.1 Use of reference methods and single donation sera (Tool I)
Total calcium and glucose
The blood donors had a healthy background and they were fasting prior to blood
donation, which resulted in normal and quite similar concentration levels of total
calcium and glucose. The reference method values with uncertainties (Confidence
Interval, C.I. 95%) for the six single donation sera are summarized below in Table 1.
Ion chromatography was operated under the condition of a maximum bias of 0.7% and
ID-GC-MS under the condition of a maximum bias of 0.9%.
Table 1. Target values for total calcium and glucose.
Total calcium concentration
and uncertainty per sample
Glucose concentration
and uncertainty per sample
Serum
sample ID
Mean (mmol/l) (C.I. 95%) Mean (mmol/l) (C.I. 95%)
ST66 2.340 (2.319 to 2.361) 4.706 (4.682 to 4.729)
H54 2.358 (2.332 to 2.384) 5.107 (4.995 to 5.219)
EP49 2.371 (2.350 to 2.392) 5.779 (5.658 to 5.900)
SR57 2.422 (2.390 to 2.453) 5.719 (5.616 to 5.822)
ST73 2.486 (2.464 to 2.508) 5.995 (5.959 to 6.031)
HX97 2.561 (2.533 to 2.589) 6.279 (6.216 to 6.342)
The imprecision of the total calcium and glucose measurements performed by the QSL-
Finland -study participating laboratories were calculated from the mean values derived
from two duplicate measurements on three consecutive analyzing days. The number of
reported total calcium and glucose measurements was 27 each. Within the laboratories,
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the mean CV% varied from 0.2% to 4.4% in total calcium measurements, respectively
from 0.2% to 5.2% in glucose measurements.
The deviations from the target values were calculated as mean bias percentages per
laboratory. The lowest mean bias% found in total calcium measurements was -0.7%
while the highest mean bias% was 5.0%. As glucose was measured, the lowest mean
deviation from the reference method value was 0.0% and the highest 3.7%.
1.2 Evaluation of the uncertainty of measurement (Tool II)
The results from the use of this tool are based on the quantities and their uncertainties
listed in Table 2.
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Total calcium
Three cases were studied:
· Case 1 - Uncertainty sources of the analytical phase were considered.
· Case 2 - Also the pre-analytical work (sampling, sample pretreatment and storage)
was considered.
· Case 3 - The patient-related uncertainty source (intra-individual biological
variation) was added in the evaluation.
The relative contributions of the uncertainty components per cases were expressed as
index percentages. The higher the index was, the stronger was the contribution to the
evaluated uncertainty budget. Both in case 1 and case 2, the standard uncertainties of the
normalized and blank-corrected absorbance signals of sample solution and calibrator in
cuvette and substance concentration of calcium in calibrator solution had the strongest
contributions to the combined standard uncertainties. In case 3, the intra-individual
effect had a dominant influence to the uncertainty budget (Figure 2).
The results from the evaluation of the uncertainty of total calcium measurement in serum
were calculated as combined standard uncertainties and relative expanded uncertainties
both expressed in mmol/l and percentages (Table 3).
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Table 3.  Results (mmol/l), combined standard uncertainties (mmol/l and %) and
relative expanded uncertainties (mmol/l and %) for the substance
concentration of total calcium.
Calcium
Results
Case 1 Case 2 Case 3
Substance concentration of Ca, c’x
(mmol/l)
2.530 2.530 2.530
Combined standard uncertainty,
uc(c’x) (mmol/l and %)
0.048
(1.9%)
0.051
(2.0%)
0.070
(2.8%)
Relative expanded uncertainty
(k=2), U(c’x) (mmol/l and %)
0.096
(3.8%)
0.102
(4.0%)
0.140
(5.6%)
Glucose
Three cases were studied:
· Case 1 - Uncertainty sources of the analytical phase were considered. A sample
dilution outside the measurement device was considered in the uncertainty
evaluation.
· Case 2 - Also the pre-analytical work (sampling, sample pretreatment and storage)
was considered. A sample dilution outside measurement device was added in the
evaluation.
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· Case 3 - The patient-related uncertainty source (intra-individual biological
variation) was added in the evaluation. The measured glucose concentration fell
within the expected range and no dilution was included in the analytical phase.
In case 1 and case 2, the uncertainty sources from the sample dilution and the allowed
drift in the instrument sensitivity had the strongest influence to the uncertainty budgets.
A distinct finding from the strong effect of intra-individual biological variation related
to other uncertainty sources was made (Figure 3). The uncertainty budgets of the
evaluation of the uncertainty of glucose measurement in serum in the three studied cases
are summarized in Table 4.
Table 4. Results (mmol/l), combined standard uncertainties (mmol/l and %) and
relative expanded uncertainties (mmol/l and %) for the substance
concentration of glucose.
Glucose
Results
Case 1 Case 2 Case 3
Substance concentration of glucose,  c’x
(mmol/l)
45.83 45.83 6.027
Combined standard uncertainty, uc(c’x)
(mmol/l and %)
0.562
(1.2%)
0.580
(1.3%)
0.421
(7.0%)
Relative expanded uncertainty (k=2),
U(c’x) (mmol/l and %)
1.12
(2.4%)
1.16
(2.6%)
0.842
(5.6%)
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1.3 Assessment of performance characteristics (Tool III)
The analytical performance and suitability for the intended use of two POCT glucose
meters, GlucoTouchTM and Super Glucogard IITM, were studied. The outcome was
compared to the specifications informed by the manufacturers and/or to medical needs
(Table 5).
1.4 Internal quality control (Tool IV)
Primary double screening by cytotechnologists
The number of double-screened Pap smears out of the total number of investigated Pap
smears was 119/87409 during 1996-1999 at Medix. In the gynecological cytology IQC
processes following parameters were screened and evaluated:
· adequacy of diagnostic cellular material
· microbiological findings
· hormonal effects
· leukocyte count
· inflammatory reaction
· cellular atypia
· Papanicolaou classification.
First, excellent inter-observer (n=5) correlation was found in the primary double
screening. This resulted from the following findings during 1996-1999:
· estimation of the adequacy of diagnostic cellular material - 99% inter-observer
agreement
· estimation of microbiological flora - 95% inter-observer agreement
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· estimation of hormonal effect - positive trend in inter-observer agreement, although
non-significant (p = 0.050)
· less than 10% intra-observer major disagreements
· significant improvement of accuracy in the inter-observer estimation of
inflammatory findings (p = 0.001).
Secondly, this study revealed significant individual differences in evaluating cellular
atypia, failure and disagreement in benign atypia estimations and failure in primary
classification as Papanicolaou class 2 versus class 3.
The affects of intra-uterine device, patient age and hormone replacement treatment on
the cytology outcome in Pap smears were categorized as (1) major disagreement, (2)
minor disagreement and (3) full agreement (Table 6).
Table 6. Summary of the effects of the intra-individual factors affecting on
cytology outcome in primary double screening of Pap smears.
Intra-uterine device Effect on cytology outcome
Leukocyte count No (p > 0.050)
Inflammatory reaction No (p > 0.050)
Cellular atypia Yes (p = 0.001)
Age
Hormonal effects Yes (p = 0.013)
Leukocyte count No (p > 0.050)
Inflammatory reaction No (p > 0.050)
Cellular atypia No (p > 0.050)
Hormone replacement treatment
Hormonal effects Yes (p = 0.013)
Inflammatory reaction Yes (p = 0.044)
Cellular atypia Yes (p = 0.006)
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Review of the pathologists
The number of reviewed Pap smears out of the total number of investigated Pap smears
was 354/87409 during 1996-1999 at Medix. Three of eight senior pathologists
reviewed 75% of the quality control Pap smears. This internal quality control process
covered re-evaluation of the subsequent parameters with following results between the
senior pathologists:
· estimation of good quality in staining – 99% full agreement
· evaluation of the quality of primary screening – 80% full agreement
· assessment of findings and conclusions – 77% full agreement
· assessment of Papanicolaou class – 99% full agreement
· estimation of delay in reporting – 71% full agreement.
1.5 Method validation and result level verification (Tool V)
The linearity test of the new ion selective electrode method was accepted at a
concentration range from 0.10 mmol/l to 4.00 mmol/l of lithium in serum. The
measurement range for lithium reported by the manufacturer was thus verified. During
the method validation, the inter-assay variation of the proposed method was superior to
the specifications given by the manufacturer. At the six-month checkpoint, higher
imprecision was found. The relative bias percentages from EQA consensus mean
values, were matched as investigated during the method validation and during the
following six months after acceptance to routine analyses. As two EQA samples were
analyzed, the results with the new ion selective electrode method deviated more from
two reference method values established by flame emission photometry than from the
corresponding consensus mean values (Table 7).
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1.6 Internal audits (Tool VI)
The interviewed medical laboratory personnel had on average a long history with the
same employer. Seventy three per cent had worked at Medix for more than 10 years.
One of the main findings from the questionnaire revealed that the majority of those who
had no previous experience of performing internal audits (83%) were not willing to
participate in these quality actions. More than half of the interviewed (66%) stated that
the training obtained for internal audits was adequate and that the time put to audits was
sufficient (69%). There were strong opinions (86%) about the busy working
environment during the audit events. Audit programs were considered to be quite
suitable (69%), but even 18% of the interviewed laboratory workers wished for more
audit events. Twenty three percent of the workers were unpleased with the information
obtained about the outcome of the audits.
2. Results across the set of tools
Three common features with consistent effectiveness were made in the use of the six
tools (Table 8):
· demonstration and importance of laboratory performance
· demonstration and assessment of performance characteristics
· importance of personnel skills and supervision.
Firstly, laboratory performance was categorized: (1) demonstrated, (2) indirectly
demonstrated, or (3) not demonstrated. Secondly, performance characteristics were
either (1) demonstrated (shown) or (2) not demonstrated. Thirdly, personnel skills and
supervision was ranked as either (1) important or (2) needed (Table 8).
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Essential need for the use of international standards and guides in addition to the
compliance with directives was detected.
Traceability was directly associated to the use of reference methods and single
donation sera (Tool I) and to the evaluation of the uncertainty of measurement (Tool II).
Non-traceability and inaccuracy were very evident when the performance of the two
POCT glucose meters was estimated (Tool III). Complying with quality assurance
processes in the frame of international standards and guides became essential due to
lack of traceability in pattern recognition and subjective interpretation (Tool IV). The
novel ion selective electrode method was validated and the result level two-
directionally verified with well-established method validation procedure, although
traceability could not be indicated (Tool V). Managerial laboratory performance could
be improved according the outcome of the questionnaire on internal audits, even if the
audits, as a part of quality actions, had been regularly and efficiently performed (Tool
VI).
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DISCUSSION
An accuracy-based measurement system stresses traceable measurements when
possible. Today, the variety of analytes and measurements systems in the special fields
of laboratory medicine cannot guarantee metrological traceability whether it would be
possible or not. This makes the availability of international standards and guides
important. Table 9. summarizes the outcome of the use of the set of tools.
Table 9. Outcome from the use of the set of tools I-VI.
Set of tools Traceability International
standards and guides
Use of reference methods and single
donation sera (Tool I)
Demonstrated Needed
Evaluation of the uncertainty of
measurement (Tool II)
Demonstrated Needed
Assessment of performance
characteristics (Tool III)
Not demonstrated Needed
Internal quality control (Tool IV) Not demonstrated Needed
Method validation and result level
verification (Tool V)
Not demonstrated Needed
Internal audits (Tool VI) Not demonstrated Needed
I Tool: Use of reference methods and single donation sera
The use of Tool I concerns the assessment of the-state-of-the-art accuracy of serum total
calcium and glucose measurements in a shot of Finnish medical laboratories. The two
analytes were chosen to exemplify medical importance, availability of reference
methods, and standardized routine methods. Single serum donations served as testing
material (Table 8.).
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The set-up of the QSL-Finland -study included two primary utensils. The first one being
the utilization of reference methods with high accuracy and certified reference materials
in producing reference method values. This was to ensure the unbroken traceability
chain between field methods and definitive/reference methods as described for an
accuracy-based measurement system9, 25 (Table 9.). Ion chromatography, as potential
reference methodology was used for the determination of total calcium35, 36, respectively
ID-GC-MS for the determination of glucose33, 34.
Secondly, the arrangements of the QSL-Finland -study based on sera from single
donations to minimize the possible matrix effects often met with control samples in
EQA schemes160, 33 (Table 8.). Optimally, inter-laboratory comparisons would utilize
commutable reference material with traceable target values in assessing the
comparability between laboratories and the difference between the observed values
and the true value23. Therefore, the biases and comparisons to current quality goals
were evaluated on the basis of true values although with limited concentration ranges of
both analytes. This may have resulted in under-estimated biases, because the samples
represented normal values, where the calibration function is at its best. As such, the
current study represented a small-scaled, but compact national inter-laboratory
comparison with an optimal set-up, even though not so convenient to reorganize more
frequently.
The method and calibrator assortment was broad in the measurements of total calcium
and glucose among the QSL-Finland participants. This was not a surprising finding
because typically numerous different measurement systems (methods, calibrators and
instruments) do exist for each measurand in clinical chemistry. System-independent
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calibration was found in both total calcium and glucose methods.  This diversity of
calibration set-ups may indicate either lack of faith in the accuracy of the methods or
purposeful minimization of bias (Table 8).
The measurement quality of both analytes was assessed in the co-operating
laboratories. EGE-Lab recommends applying the biological approach for analytical
specifications136 (Table 9.). In 1999, the outcome from the Stockholm Consensus
Conference strongly advocated this approach157. With the exception of four out of 27
reported results, the state-of the-art quality goal for total calcium, imprecision, 1.5%
derived from biology was fulfilled. Large biases in reported calcium results predicted
problems among many participants. This might be due to unsuccessful method
calibration, method unspecificity, or use of empirical factors. Total allowable error of
total calcium measurements, both the most stringent derived from biology, 2.5% and the
national EQA limit, 3.0% was exceeded by all laboratories with one exception.  The
superiority of accredited laboratories could not be praised because one accredited
method exceeded even the German limit, 10%.
There seemed to be no major problems with the trueness and precision of glucose
measurements, because only seven methods resulted in a range beyond the proposed
limits derived from biology: 1.9% for trueness and 2.2% for precision. Repeatedly, a
single accredited method once more was above the others in bad performance as
precision was assessed.
The use of Tool I indicated cross-sectional laboratory performance in Finland (Table
8.). The evaluation of performance characteristics in terms of bias and imprecision
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showed a need for updating the routine quality assurance procedures by supervision,
such as well-established IQC (Table 9.). In this context, fulfilling the requirements of
international standards in the sense of accreditation did not give any indication as to be
a guarantee for good measurement quality.  Analogous conclusions were made from the
IRMM International Measurement Evaluation Programme, IMEP-7: Inorganic
components in human serum133.
II Tool: Evaluation of the uncertainty of measurement
The aim of the use of Tool II was to emphasize the need for expressing measurement
quality in terms of measurement reliability or uncertainty.  Evaluation of uncertainty of
measurement of total calcium and glucose determinations was exemplified and
laboratory performance indirectly demonstrated (Table 8.).  At present, an increasing
pressure exists for medical laboratories to express and release information of their
measurement quality109, 119. Evaluation of uncertainty of measurement offers excellent
means for this where possible. The EURACHEM/CITAC Guide four-step-procedure
was followed in this study115 (Table 9.).
In addition to regular and special EQA schemes available for medical laboratories, the
role of IRMM has been significant in organizing international inter-laboratory
comparisons in the frame of IMEP of which the seventeenth round, IMEP-17 has been
presently on-going132. The close co-operation between IRMM, the European Committee
for External Quality Assessment Programmes in Laboratory Medicine (EQALM) and
the Committee for Analytical Quality (C-AQ) of the IFCC resulted in a conclusion that
there is a need for education of the uncertainty evaluation among laboratory
professionals (Table 8.). As the IMEP programs strongly focus to traceability,
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uncertainty, use of metrological reference values, traceable to SI system of units, the use
of Tool II was further supported (Table 9.).
The evaluation process applies data from observations and the calibration function,
which is inherently related to quantitative analyses. This emphasizes the character of
the calibration and/or reference material, its traceability, and uncertainty. The Essential
requirements, Annex 1 in the EC directive set for IVDs gives notice of the requirements
for manufacturers about the traceability of values assigned to calibrators and/or control
values12 (Table 9.).
Until today, extremely limited information about the uncertainty of the calibrators used
in the field methods has been available for laboratory professionals. This information
about the uncertainty of the total calcium and glucose calibrator, and other investigated
uncertainty sources was obtained from the manufacturer of the studied analyzing system
(Table 9.). The calibration function is crucial in quantitative analyses. The findings
from the uncertainty budgeting of total calcium determination gave support to this. The
standard uncertainty of the substance concentration of the calcium calibrator showed a
significant relative contribution to the combined standard uncertainty as the individual
components were investigated (Figure 2). This was also true with glucose measurement
in Cases 1 and 2 (Figure 3).
Medical laboratory analyses consist of several phases and thus include a number of
possible uncertainty sources, major or minor. The four-step-procedure was found to be
an excellent method of iterating the entire measurement process. Critical examination of
each single phase results in the best possible evaluation of uncertainty. It is intended
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that data on observations from IQC and method validation are used in the evaluation
process and this data is usually available. As it was with this study, data from literature
may also be applied.
Interestingly, in the pre-dilution phase the volume of the diluent and the volume of the
sample to be diluted had major relative contribution to the combined standard
uncertainty (Figure 3).
It may be claimed that pre-analytical factors such, as intra-individual biological
variation should be beyond the scope of uncertainty budgeting when measurements are
involved. However, adding this factor to the other quantities resulted in a surprisingly
large relative contribution in both determinations (Figure 2 and Figure 3).
Consequently, it is of utmost importance to set quality goals, and they should be based
on biological variation.
The outcome of the use of Tool II was an example of the usefulness of the evaluation of
uncertainty of measurement in routine clinical chemistry. Evaluated uncertainty of
measurement as a measure of reliability is a valuable performance characteristic and it
can be indirectly used when measuring laboratory performance, i.e. assessing the
success in EQA schemes. The findings from the use of Tool II support this statement.
Much of the purpose of this study was educational and it is argued that practical
guidelines are still needed (Table 9).
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III Tool: Assessment of performance characteristics
IVDs for SMBG belong to List B of diagnostic devices according to Annex 2 in the
Directive 98/79/EC on IVDs12. It stipulates that calibrators and reference materials of
SMBG meters belong to the legislative inspection and approval whenever trading and
usage for monitoring purposes is concerned in the European Community. In the US,
CLIA'88 classifies SMBG meters into the category of waived tests64, 97. More than two
hundred glucose monitoring devices, including test strips are listed in the database of
FDA's Center for Devices and Radiological Health161. This supports the essential role
of glucose meters in the family of all POCT systems.
In addition to self-monitoring, blood glucose meters are widely used in hospitals, health
care centers, and doctors' offices. Quantitative results are produced and used for
important decision-making. For this reason, analytical performance and fit-for-purpose
evaluation of the device is of the utmost importance. Generally, analytical performance
should not be judged if quality goals do not exist. The Directive 98/79/EC defines the
essential criteria while clinical chemistry expertise is needed for determination of
performance criteria154, 155.
By investigating any analyzing system, performance characteristics, even selected ones
may be evaluated and assessed (Table 8.). The use of Tool III was shown with the
comparison of two SMBG meters, the GlucoTouchTM and the Super Glucogard IITM
(Table 5.). The evaluation was based on both self-made observations and
manufacturers' specifications. Laboratory performance in situ, was beyond the scope of
this study, although uncertainty of measurement was discussed when clinical laboratory
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values were concerned (Table 8.). In any case, one might regard testing at the hospital
wards as satellite laboratory work.
Reference methods and reference materials have been available for the measurement of
glucose for decades, but the traceability of the two SMBG test systems remained
undesignated (Table 9.). No such data was available from either of the manufacturers or
their representatives. Dedicated glucose analyzing systems for the calibration of SMBG
meters exists, but traceability is scarcely discussed162, 163. Under the circumstances of
this study, the calibration data of both meters was insufficient. The GlucoTouchTM did
measure the plasma glucose level as assigned by the manufacturer, while the trueness of
Super Glucogard IITM's especially at the hypoglycemic levels remained quite dubious.
ISO quality system standards set the requirements for companies that wish to conform to
the standards and certification. The disciplined design control may not have been in
place if the intended use and the performance of a POCT device did not fulfill the
current requirement92. Pitfalls may exist in the family of SMBG meters and the current
example of the use of Tool III certainty demonstrated it. Fortunately, the Directive
98/79/EC on IVDs has come into force and will filter the poorly performing newcomers
out of this pool of very diverse analyzing systems. International standards strengthen the
triangle of IVD end-users, manufacturer's and official controlling bodies.
IV Tool: Internal quality control
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to represent a field of laboratory medicine where traceability to SI cannot be shown.
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Approximately 95% of all medical laboratory testing still falls in the range of
metrological untraceability39 and much of it will remain in this group as e.g. cellular
testing material is often concerned. Laboratory accreditation according to the current
standard, ISO/IEC 1702584 strongly advocates traceability to SI where possible. As
cytopathology and Pap smear testing are concerned, other means of demonstrating the
measurement quality and laboratory performance or competence need to be used (Table
9.).
The methods of IQC in gynecological cytopathology, double screening and pathologist
reviewing differ from those of the traditional ones, mostly related to clinical chemistry
and more familiars to clinical biochemists. In fact, error detection and error prevention
are the basic goals in internal quality assurance procedures regardless of the specific
field of laboratory medicine. Primary screening and investigation of all testing material
by a senior pathologist was a standard testing procedure from 1996-1999 at Medix.
Regarding error detection, Tool IV was exemplified by factors affecting the
measurement quality of primary screening.
The laboratory report of a Pap test result contains several parameters first pre-screened
and then investigated by pathologist. Seven parameters belonged to the standard testing
procedure. Reference methodology, although not a primary method of measurement by
definition, the conventional Papanicolaou’s staining and cell morphology based on the
Bethesda System42 was used and regarded as the best possible one for routine analyses
(Table 9.). Inter-observer correlation and review of the pathologists were investigated
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observer (n=5) correlation was excellent. A positive trend with time although
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statistically non-significant in inter-observer agreement on the estimation of hormonal
effect was found a consequence of the feedback meetings between senior pathologists
and cytotechnologists. A similar reason for the improvement of the accuracy in the
inter-observer estimation of inflammatory findings was concluded.
The IQC test material was grouped in terms of intra-individual characteristics, such as
intra-uterine device, age and hormone replacement treatment to find out the effect of
these factors on the primary double screening. Major and minor disagreements, and full
agreements were evaluated (Table 6.). Less effect than expected was found.
Nevertheless, hormone replacement treatment and the presence of intra-uterine device
effected significantly on pre-screening of cellular atypia. It was not surprising that the
results from the investigation of patient’s age and the evaluation of hormonal effects
strongly indicated the difficulty of screening of this parameter among patients younger
than 47 years.
The pathologists reviewed 354 of 87409 Pap smears between 1996-1999 at Medix. Out
of this reviewed sample pool, three of the eight senior pathologists re-evaluated 75% of
the IQC samples. The low number of the others’ reviews made the statistical
calculations impossible. Anyway, they agreed on the quality of the stained Pap smears
(99%) and primary screening (80%). This is a sign of good laboratory practices and
skillful cytotechnologists. Reviewing by senior pathologists is always done long after
the laboratory reporting. In this context, possible error detection does not occur in an
optimal time. On the other hand, evaluation of this performance characteristic should
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V Tool: Method validation and result verification
In the course of a continuously developing medical laboratory environment, method
validation and verification of novel or replacement test methods of measurements is
persistent work among clinical biochemists and clinicians. Frequently, these kinds of
tasks are performed under limited time schedules. Under these circumstances, much
weight is placed on established validation and acceptance procedures. Although the
first method evaluation schemes were introduced already three decades ago100, these
procedures do not necessarily belong to basic quality tools when implementing quality
systems in medical laboratories today.
The aim of using Tool V was to introduce a practical validation example taken from
routine medical laboratory production. There are four main stages: planning,
performing, evaluating and verifying are typical elements in a common validation
process. First and not least, it is postulated that methods of measurement should be
made to satisfy an agreed requirement27. Validation parameters should be defined in
each case to fulfill practicability, reliability and cost effectiveness of the procedure.
For this reason, the following utensils of Tool V were selected as the necessary
validation parameters: testing of linearity, verification of measurement range, and
evaluation of imprecision and bias.
Verifying by IQC and EQA closes up the validation process75. Thus, the laboratory
performance was indirectly demonstrated at the 6-month checkpoint by EQA (Table 8.).
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metrological traceability (Table 9.). During the planning, a decision was made that
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certified reference materials would not be purchased for a single method validation due
to their high costs (Table 9.). Fortunately, two EQA schemes offered reference method
values on serum lithium at the 6-month checkpoint. The results showed that modeled
laboratory performance with EQA past samples was better than at the 6-month
checkpoint. This does not naturally make the EQA past samples useless in method
validation, but necessary for future comparison.
The main indications of the determination of serum lithium are therapeutic drug
monitoring and avoidance of intoxication. As the therapeutic range is narrow for serum
lithium, 0.60 - 1.2 mmol/l, excellent precision is required. Verification of the
imprecision at the 6-month checkpoint revealed similar finding as with the bias. The
observed precision of the novel ion selective electrode method during the method
validation was better than assigned by the manufacturer, but similar findings could not
be made at the 6-month checkpoint even with the system controls. The precision of the
system-independent control was superior to that of system controls, but did not quite
fulfill the national criteria of 2%.
The method comparisons with patient samples (n = 62) showed biases between all
methods and the CIs of the intercepts did not overlap. This finding was nevertheless in
agreement with the outcome from the evaluation of relative biases from consensus mean
values although the use of the Marchandise equation loses the sign of bias.
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VI Tool: Internal audits
Measurement quality is certainly closely related to technical competence. The
requirements in the current standards, ISO/IEC 1702584 and EN/ISO 1518985 cover the
laboratory management as well. The principles of total quality management stress to the
Plan-Do-Check-Adjust -approach46 and internal audits Tool VI should be utilized as an
essential management tool. In the frame of laboratory accreditation or certification,
internal audit in medical laboratories is a rather new concept and it could be predicted
that the character of even this management tool would change with time.
The idea of operating with Tool VI was to check and then adjust the established
practice of internal audits by finding out about the opinions of the laboratory personnel.
Integrated participation in quality actions is essential. The lack of experience among the
personnel to perform internal audits appeared to be the reason for stumbling in the
yearly audit planning.  It was found that continuous encouragement for auditing had not
been sufficient (Table 8.). Despite the existing documented practice, i.e. internal audit
as a quality assurance process, the necessity for training and supervision and
importance of personnel skills even in this practice was observed (Table 9.).
Nearly one fifth (18%) of the interviewed laboratory workers wished for more audit
events than what was normally planned and accomplished, while the rest were satisfied
with the current procedures. One could consider this as a positive way of quality
thinking. Willingness to improve one's work is a favorable sign towards continuous
quality improvement. Less surprising was that more than one fifth (22%) was
disappointed with the flow of information regarding the outcome of the internal audits.
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SUMMARY AND CONCLUSIONS
Medical laboratories have faced tremendous changes in refining the idea of
measurement quality during the last fifteen years. Although quality is not a novel
invention, the quality boom has indeed produced international standards, guides, and
recommendations to be applied in the field of medical laboratory science. This work
continues within several expert groups worldwide. Consequently, a quality-oriented
way of laboratory working has changed the general attitude towards transparency,
systematic, and traceability by definition.
As a selection of the numerous quality tools that are available, the presented set of
Tools I-VI indicated practicability and usefulness. Measurement quality was shown in
terms of laboratory performance, performance characteristics, personnel skills, and
supervision.
The use of the presented set of tools strongly advocates the need and necessity of
international standards and guides. It is important to understand that all test methods
within the many fields of laboratory medicine should be treated under harmonized rules
of quality assurance whenever a quality-oriented way of laboratory working is
required.
The use of primary methods of measurements ties the results to SI at the top level of an
accuracy-based measurement system. Traceable reference method values offer the best
possible means for demonstrating the laboratory performance whenever possible. To
avoid high costs reference method values combined with commutable control material
should be at least regularly available for as many inter-laboratory comparisons and
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EQA schemes as possible in the future. Medical laboratory professionals should pay
more attention to the calibration and IQC procedures of their field methods
simultaneously as manufacturers are fulfilling the requirements set in the IVD directive.
It is concluded that laboratory accreditation in its present form does not ensure good
measurement quality.
The importance of traceability and evaluation of uncertainty of measurement are
strongly focused upon in the IMEP program. As an essential performance characteristic,
uncertainty of measurement in quantitative analyses reflects the measurement quality in
the best possible way. The four-step uncertainty evaluation process ensures a thorough
investigation of a measurement procedure. Notwithstanding, a brush-up of skills and
metrological approach among laboratory professionals is still required. The
availability of sophisticated software tools does not diminish this need.
IVDs used for SMBG represent a group of POCT instrumentation by which more on-
site decisions are made than with any other analyzing systems. Precision is generally
regarded as a more important performance characteristic in monitoring than trueness.
Although glucose meters are listed in Annex 2 of the IVD directive, no traceability
could be shown. Furthermore, measurement capabilities should comply with the
manufacturer’s specifications and the intended use with possible limitations should be
clearly assigned. It was concluded that co-operative supervision is needed whenever
the POCT devices are under the responsibility of central laboratory. Purchasing and
performance evaluation combined with IQC should be in the hands of laboratory
personnel. The current international standards should strengthen the triangle between
IVD end-users, manufacturers and authorities.
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In the measurement field of pattern recognition and subjective interpretation,
metrological traceability cannot be demonstrated today. Other quality tools, such as
IQC are then strongly weighted. Double screening or reviewing just in terms of
controlling, does not result in the improvement of diagnostic quality as such. It was
found that, feedback meetings resulted in harmonized evaluation of cellular material and
error prevention. IQC means extra workload in cytopathology due to its manual and
time-consuming nature of analysis. There are good grounds for lowering the frequency
of double screening if a high probability of error detection can be demonstrated, if the
inter-observer correlation is good, and if the technical competence of the pre-screening
has been proved. The outcome of this presented quality tool may be used as a measure
of diagnostic reliability at its best.
Laboratory tests should be made to fulfill the needed requirements. That is what
analytical specifications are needed for. Well-planned, performed, documented, and
verified method validation is a prerequisite of reliable routine methods. The awareness
of performance characteristics is essential for re-establishing IQC procedures and
assessment of EQA outcome. Validation parameters shall be rationally defined case by
case including both standardized and non-standardized test methods. Careful validation
of accredited methods should not be kept separate from the non-accredited ones.
Manufacturer’s specifications can be used as additional and supporting data for
validation but not as a sole source of data. The use of EQA past samples where
possible offer valuable means in predicting the future success in EQA schemes and in
verifying the result level between novel and current methods of measurement. The use
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of EQA samples with reference method values can be utilized in the evaluation of bias
if available.
Good laboratory practice means re-evaluating the established processes. Today,
internal audits are a documented management process in every medical laboratory with
a quality system. It was concluded that carrying out and completing this quality action
needs updating in its management. Brief questionnaires can be used with good results
whenever one wishes the current processes to be improved. Laboratory performance in
the meaning of management success could be demonstrated. As a summary, additional
training and improving the internal information flow were clearly needed.
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ERRATUM
I Linko S, Himberg J-J, Thienpont L, Stöckl D, De Leenheer A. Assessment of the
state-of-the-art trueness and precision of serum total-calcium and glucose measurements
in Finnish laboratories - the QSL-Finland -study. Scand J Lab Invest 1998; 58:229-
240.
Then mean CV% per laboratory is missing from the table in the original reprint.
TABLE VI. Imprecision of glucose measurements, CV% (n=6)
Sample ST66 H54 EP49 SR57 ST73 HX97
RMV (mmol/l) 4.706 5.197 5.779 5.719 5.995 6.279 Mean CV%
Lab CV% CV% CV% CV% CV% CV% per laboratory
O 0.8 0.0 0.0 0.0 0.0 0.7 0.2
P 1.6 2.1 1.6 0.9 1.8 1.2 1.5
W 0.8 0.9 0.9 1.2 1.5 0.0 0.9
Y 3.4 2.1 2.7 2.2 2.1 2.4 2.5
B 1.8 0.7 0.0 0.8 0.8 0.8 0.8
K 1.0 0.8 0.9 1.2 0.8 0.7 0.9
V 2.2 2.0 1.6 2.0 1.8 2.6 2.0
X 3.4 2.7 2.4 3.6 4.0 3.7 3.3
A 2.0 1.6 1.3 3.2 0.8 1.5 1.7
Da 1.1 0.7 1.3 0.9 0.8 0.7 0.9
E 1.6 1.9 1.5 2.0 1.8 2.1 1.8
M 2.8 1.7 3.6 3.3 3.4 1.4 2.7
N 1.1 1.1 0.9 0.8 1.0 0.7 0.9
Qa 1.5 1.3 1.8 0.0 0.8 0.9 1.1
Ua 5.2 3.7 5.3 5.6 5.1 6.2 5.2
Ub 1.5 2.1 1.3 1.4 0.8 4.3 1.9
H 1.1 0.9 1.9 0.2 1.2 1.3 1.1
J 1.6 2.7 1.4 1.3 1.2 1.7 1.6
Qb 3.2 1.7 1.3 2.8 3.2 1.5 2.3
S 2.6 1.0 1.5 1.6 2.3 1.3 1.7
L 4.1 2.9 2.7 5.0 3.2 3.7 3.6
T 2.1 2.7 3.1 2.7 1.6 3.0 2.5
G 1.1 1.5 1.2 1.3 1.4 1.3 1.3
R 1.6 2.2 1.7 3.0 0.8 1.2 1.8
C 0.8 0.9 2.1 0.6 0.8 0.6 1.0
Db 0.8 1.4 0.8 1.3 1.1 1.3 1.1
F 0.8 1.8 0.9 0.6 0.6 0.8 0.9
 Min CV%all = 0.0 (n=162); Max CV%all =6.2 (n=162)
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